Pharmaceutical News

RSS

Telomerase inhibiting drug induces morphologic, molecular, clinical remissions in myelofibrosis patients

metelstat, a novel telomerase inhibiting drug, has been found to induce morphologic, molecular and clinical remissions in some patients with myelofibrosis a Mayo Clinic study has found. The results were presented today at the 2013 American Society of Hematology Annual Meeting in New Orleans.

6 Dec 2013

Combination of preventive and therapeutic moxibustion has beneficial effect for Alzheimer's disease

An increasing number of clinical and animal studies have confirmed that acupuncture is effective for the treatment of Alzheimer's disease. Moxibustion is reported to be more effective than electro-acupuncture for improving space-recognizing memory ability in aged mice, suggesting that moxibustion is another alternative or complementary therapy used to treat Alzheimer's disease.

6 Dec 2013

Study results show insulin sensitizers reduce risk of cancer in female patients with type 2 diabetes

A Cleveland Clinic-led study shows that a specific type of diabetes drug can decrease the risk of cancer in female patients with type 2 diabetes by up to 32 percent.

5 Dec 2013

Older people ingest too much magnesium, vitamin E in the form of dietary supplements

Many older people are ingesting too much magnesium and vitamin E in the form of dietary supplements. This was discovered by scientists of the Helmholtz Zentrum München in a population-based study; their results have been published in 'The Journal of Nutrition, Health and Aging'.

5 Dec 2013

Mylan Pharmaceuticals introduces Cabergoline Tablets USP, 0.5 mg

Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Cabergoline Tablets USP, 0.5 mg. Cabergoline Tablets USP are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product.

5 Dec 2013

First Databank starts publishing NADAC pricing file released by CMS

First Databank (FDB), the leading provider of clinical drug knowledge that helps improve medication-related decisions and patient outcomes, today announced it has begun publishing the National Average Drug Acquisition Cost (NADAC) pricing file recently released by The Centers for Medicare & Medicaid Services (CMS).

5 Dec 2013

EMA expands administration options for Hizentra

CSL Behring UK Ltd announced today that the European Medicines Agency (EMA) has expanded the administration options for Hizentra®▼, human normal immunoglobulin, SCIg, 20% liquid, to include dosing once every two weeks (fortnightly).

5 Dec 2013

IDSA released new guideline for vaccination of immunocompromised hosts

A new guideline released Thursday by the Infectious Diseases Society of America (IDSA) notes that most people with compromised immune systems are especially vulnerable to illness and should receive the flu shot and other vaccinations.

5 Dec 2013

VTT receives innovation prize for technological development work behind allergy vaccine

The European Association of Research and Technology Organisations EARTO has awarded VTT Technical Research Centre of Finland an innovation prize for the technological development work behind allergy vaccine.

5 Dec 2013

TB vaccine may help prevent multiple sclerosis

A vaccine used to prevent tuberculosis in other parts of the world may help prevent multiple sclerosis in people who show the beginning signs of the disease, according to a new study published in the December 4, 2013, online issue of Neurology, the medical journal of the American Academy of Neurology.

5 Dec 2013

MassBiologics gets FDA orphan drug designation for MBL-HCV1 antibody

MassBiologics of the University of Massachusetts Medical School has received an orphan drug designation from the U.S. Food and Drug Administration for MBL-HCV1, a monoclonal antibody developed to prevent hepatitis C virus recurrence in patients receiving a liver transplant.

5 Dec 2013

Roche signs research collaboration and licensing agreement with Molecular Partners

Roche and Molecular Partners AG today announced that they have entered into a research collaboration and licensing agreement to discover, develop and commercialize several proprietary therapeutics incorporating Molecular Partners' DARPin biologics conjugated to toxic agents developed at Roche for the treatment of cancer.

4 Dec 2013

FDA accepts ARCA biopharma's Gencaro IND application for atrial fibrillation

ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that the Company's Gencaro Investigational New Drug application for atrial fibrillation has been accepted by the U.S. Food and Drug Administration and is now active.

4 Dec 2013

Japanese company places order for Nutranomics’ natural testosterone booster formula

Nutranomics, Inc.("Nutranomics" or the "Company") is pleased to report that it has received a purchase order for 500,000 capsules of a natural testosterone booster formula recently developed by Nutranomics.

4 Dec 2013

Antiretroviral therapy for HIV treatment saves 2.8 million years of life in South Africa

Antiretroviral therapy for the treatment of HIV infection has saved 2.8 million years of life in South Africa since 2004 and is projected to save an additional 15.1 million years of life by 2030, according to a new study published online in The Journal of Infectious Diseases. The analysis suggests these dramatic benefits could be even greater if more aggressive HIV testing and treatment strategies are implemented.

4 Dec 2013

Researchers take important step towards development of future drugs for brain diseases

A successful joint collaboration between researchers at the Hebrew university of Jerusalem and the startup company TyrNovo may lead to a potential treatment of brain diseases. The researchers found that TyrNovo's novel and unique compound, named NT219, selectively inhibits the process of aging in order to protect the brain from neurodegenerative diseases, without affecting lifespan. This is a first and important step towards the development of future drugs for the treatment of various neurodegenerative maladies.

4 Dec 2013

Study compares efficacy and side effects of popular osteoporosis drugs

A study comparing the efficacy and tolerability of two popular osteoporosis drugs, denosumab and zoledronic acid, found that denosumab had a significantly greater effect on increasing spine bone mineral density and zoledronic acid caused more flulike symptoms.

4 Dec 2013

Takeda and Teva announce agreement related to commercialization of glatiramer acetate in Japan

Teva Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Company Limited (Takeda) today announced the signing earlier this year of an agreement in which Teva licensed to Takeda the right to commercialize Teva's innovative glatiramer acetate ( active ingredient) formulation for the treatment of multiple sclerosis, in Japan.

4 Dec 2013

New male contraceptive pill could soon be available

A new male contraceptive could be on the horizon after scientists identified a novel way to block the transport of sperm during ejaculation.

4 Dec 2013

People who rely on visual identification of medications may risk poor BP control

People who identify their blood pressure medications by shape, size and color instead of by name may risk poor blood pressure control and increase their risk of hospitalization, finds a recent study in the Journal of Health Communication: International Perspectives.

4 Dec 2013

Pharmaceutical News

Telomerase inhibiting drug induces morphologic, molecular, clinical remissions in myelofibrosis patients

Combination of preventive and therapeutic moxibustion has beneficial effect for Alzheimer's disease

Study results show insulin sensitizers reduce risk of cancer in female patients with type 2 diabetes

Older people ingest too much magnesium, vitamin E in the form of dietary supplements

Mylan Pharmaceuticals introduces Cabergoline Tablets USP, 0.5 mg

First Databank starts publishing NADAC pricing file released by CMS

EMA expands administration options for Hizentra

IDSA released new guideline for vaccination of immunocompromised hosts

VTT receives innovation prize for technological development work behind allergy vaccine

TB vaccine may help prevent multiple sclerosis

MassBiologics gets FDA orphan drug designation for MBL-HCV1 antibody

Roche signs research collaboration and licensing agreement with Molecular Partners

FDA accepts ARCA biopharma's Gencaro IND application for atrial fibrillation

Japanese company places order for Nutranomics’ natural testosterone booster formula

Antiretroviral therapy for HIV treatment saves 2.8 million years of life in South Africa

Researchers take important step towards development of future drugs for brain diseases

Study compares efficacy and side effects of popular osteoporosis drugs

Takeda and Teva announce agreement related to commercialization of glatiramer acetate in Japan

New male contraceptive pill could soon be available

People who rely on visual identification of medications may risk poor BP control

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News